Qiagen Looks to Acquire Cellestis to Enhance Portfolio of Molecular Tests in Infectious Disease | GenomeWeb

By Turna Ray

Qiagen's proposed acquisition of Australian testmaker Cellestis would give the firm a test portfolio that will work in concert with its existing tests and allow it to improve diagnostics for preventing disease and personalizing care.

The A$341 million ($355 million) acquisition plan, announced this week, is still subject to approval by Cellestis' shareholders. Qiagen projects that the transaction will be approved in June, when Cellestis' shareholders are scheduled to meet.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.